<DOC>
	<DOC>NCT02623751</DOC>
	<brief_summary>The primary objective of the open-label, dose-escalation study is to investigate the safety of single-dose monotherapy and repeated-dose of KHK2375 combined with exemestane in female subjects with advanced or recurrent breast cancer. The secondary objective is to investigate the pharmacokinetics and efficacy.</brief_summary>
	<brief_title>Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>Postmenopausal women aged ≥ 20 and &lt; 75 years at the time of consent; Estrogen receptor positive and/or progesterone receptors positive; HER2negative Nonresectable advanced or recurrent breast cancer previously treated with nonsteroidal aromatase inhibitor (AI), and planning to be treated with exemestane Radiation therapy or immuno therapy within 14 days before the first dose of investigational product; Chemotherapy, biological medicines, other pharmacotherapy or major surgery within 21 days before the first dose of the investigational product; Prior chemotherapies of ≥ 3 regimens for advanced or recurrent breast cancer; Ongoing treatment with other investigational product</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>